Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Registrati

Quotazioni in diretta

NVS Novartis AG

108,02

0,00 (0,00%)

27 Feb 2025 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

05/22/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Aharon Gal

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Gen 2025 a Feb 2025

Clicca qui per i Grafici di Novartis

Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Feb 2024 a Feb 2025

Clicca qui per i Grafici di Novartis

Notizie Novartis AG - NVS

BMO Expands Canadian Depositary Receipt (CDR) Lineup with 10 New Listings from Europe and Japan
Giovedì 20 Febbraio 2025 (7 giorni fa) • PR Newswire (Canada)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunedì 30 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
Lunedì 2 Dicembre 2024 (3 mesi fa) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunedì 25 Novembre 2024 (3 mesi fa) • Edgar (US Regulatory)

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Lunedì 18 Novembre 2024 (3 mesi fa) • PR Newswire (US)

Tesla Sales Drop; Intel to Exit Dow Jones After 25 Years; VKTX and ATSG Surge Over 20% Pre-Market
Lunedì 4 Novembre 2024 (4 mesi fa) • IH Market News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martedì 29 Ottobre 2024 (4 mesi fa) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martedì 29 Ottobre 2024 (4 mesi fa) • Edgar (US Regulatory)

HSBC Reports $8.5 Billion Profit; Boot Barn Announces New CEO and Projections; TMDX Drops 24%, VFC Surges 22%
Martedì 29 Ottobre 2024 (4 mesi fa) • IH Market News

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Venerdì 18 Ottobre 2024 (4 mesi fa) • PR Newswire (US)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Giovedì 17 Ottobre 2024 (4 mesi fa) • Edgar (US Regulatory)

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Giovedì 3 Ottobre 2024 (5 mesi fa) • InvestorsHub NewsWire

Più Novartis AG Articoli Notizie

Intesa Sanpaolo

ST Microelectronics

Banca Monte Dei Paschi D...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea